Atara Biotherapeutics (NASDAQ:ATRA) Price Target Lowered to $17.00 at Canaccord Genuity Group

Atara Biotherapeutics (NASDAQ:ATRA) had its price objective decreased by Canaccord Genuity Group from $21.00 to $17.00 in a research note issued to investors on Friday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the biotechnology company’s stock.

ATRA has been the topic of a number of other research reports. TD Cowen raised shares of Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. Rodman & Renshaw assumed coverage on Atara Biotherapeutics in a report on Friday, December 20th. They set a “buy” rating and a $25.00 price objective on the stock. Finally, RODMAN&RENSHAW upgraded Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, December 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Atara Biotherapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $17.75.

Atara Biotherapeutics Price Performance

Shares of NASDAQ ATRA opened at $6.57 on Friday. The stock has a market capitalization of $37.84 million, a PE ratio of -0.25 and a beta of 0.51. Atara Biotherapeutics has a one year low of $6.50 and a one year high of $39.50. The business’s fifty day moving average price is $12.52 and its 200-day moving average price is $9.99.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating the consensus estimate of ($3.77) by $0.84. The business had revenue of $40.19 million for the quarter, compared to analysts’ expectations of $23.00 million. During the same period last year, the company earned ($16.50) earnings per share. As a group, equities analysts expect that Atara Biotherapeutics will post -9.86 EPS for the current fiscal year.

Hedge Funds Weigh In On Atara Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ATRA. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Atara Biotherapeutics during the 2nd quarter valued at about $53,000. Cubist Systematic Strategies LLC purchased a new stake in Atara Biotherapeutics in the second quarter valued at approximately $79,000. State Street Corp raised its stake in Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 7,680 shares in the last quarter. FMR LLC lifted its position in Atara Biotherapeutics by 41.7% during the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after buying an additional 4,043 shares in the last quarter. 70.90% of the stock is currently owned by hedge funds and other institutional investors.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.